The SARS-CoV-2 coronavirus pandemic calls for coordinated efforts by the scientific community for the development of vaccines. The most advanced strategies have focused on modifications of technologies that were already under development for other viruses, such as SARS, MERS, and even Influenza. Classic and new technologies, such as inactivated and attenuated viruses (non-replicative and replicative), DNA and mRNA vaccines, and nanoparticles containing SARS-CoV-2 antigens, are some of the strategies currently investigated. Although there is a very high expectation for the effectiveness of the most advanced vaccine candidates, there are still no established correlates of protection. Previous experience in vaccine development for other pathogens shows that differences in vaccine formulation can result in diverse immune responses and consequently, different protective properties. Therefore the importance of continuing investigations on a broad range of strategies. Expertise in vaccine development in Brazil was refocused to the new coronavirus. Impressive collaboration between institutions will support further developments until we have available a safe, effective, and economically viable vaccine. Established competence and collaborations will allow preparedness for future challenges and can also be used to address local issues as neglected infectious diseases.

中文翻译：

---

SARS-CoV-2 疫苗的开发以及巴西如何做出贡献。

SARS-CoV-2 冠状病毒大流行需要科学界协调努力开发疫苗。最先进的策略侧重于对已经在开发的其他病毒（例如 SARS、MERS，甚至流感）的技术进行修改。经典和新技术，例如灭活和减毒病毒（非复制型和复制型）、DNA 和 mRNA 疫苗以及含有 SARS-CoV-2 抗原的纳米粒子，是目前研究的一些策略。尽管人们对最先进的候选疫苗的有效性抱有很高的期望，但仍然没有确定的保护相关性。先前针对其他病原体开发疫苗的经验表明，疫苗配方的差异可能导致不同的免疫反应，从而导致不同的保护特性。因此，继续研究广泛的策略非常重要。巴西疫苗开发的专业知识重新聚焦于新型冠状病毒。机构之间令人印象深刻的合作将支持进一步的发展，直到我们获得安全、有效且经济上可行的疫苗。既定的能力和合作将为未来的挑战做好准备，也可用于解决被忽视的传染病等当地问题。